Jose-Angel Gonzalo serves as a Principal Scientist in Immuno-Oncology at Sanofi, where he leverages over 20 years of industry expertise to drive innovative drug discovery programs. His role is pivotal in defining the mechanisms of action (MOA) for various therapeutic targets, significantly contributing to the...
Jose-Angel Gonzalo serves as a Principal Scientist in Immuno-Oncology at Sanofi, where he leverages over 20 years of industry expertise to drive innovative drug discovery programs. His role is pivotal in defining the mechanisms of action (MOA) for various therapeutic targets, significantly contributing to the advancement of Sanofi’s Immuno-Oncology pipeline. Jose-Angel is particularly adept at developing in vitro co-culture assays that facilitate the screening of bispecific nanobodies and antibodies, enabling the identification of promising candidates for further development.
His collaborative approach is evident as he works transversely across multiple platforms, including the Nanobody Research Platform and Disease Profiling & Functional Genomics teams. This cross-functional interaction not only enhances the efficiency of the drug development process but also fosters a culture of innovation within the organization. By establishing rigorous standards for the generation of multispecific molecules, Jose-Angel ensures that the therapeutic roles of these candidates are thoroughly assessed, ultimately leading to more effective treatment options for patients.
With a strong foundation in cell biology and a comprehensive understanding of biotechnology and life sciences, Jose-Angel is a self-motivated leader who thrives in team-oriented environments. His ability to manage diverse teams and navigate the complexities of the pharmaceutical industry underscores his commitment to advancing the field of Immuno-Oncology. As he continues to push the boundaries of drug development, Jose-Angel remains focused on achieving common goals that will have a lasting impact on patient care and treatment outcomes.
